Efficacy and safety of ibandronate in the treatment of opioid-resistant bone pain associated with metastatic bone disease: A pilot study

Journal of Clinical Oncology

Volumn 22, Issue 17, 2004, Pages 3587-3592

  Mancini, Isabelle ^a   Dumon, Jean Claude ^a   Body, Jean Jacques ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; CREATININE; IBANDRONIC ACID; NARCOTIC ANALGESIC AGENT; OPIATE; UREA; BISPHOSPHONIC ACID DERIVATIVE; NARCOTIC AGENT;

ARTICLE; BONE METASTASIS; BONE PAIN; BONE TURNOVER; CALCIUM METABOLISM; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; HUMAN; NEPHROTOXICITY; OPEN STUDY; PILOT STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; SCORING SYSTEM; SHORT COURSE THERAPY; UREA BLOOD LEVEL; ADULT; AGED; BONE TUMOR; DRUG RESISTANCE; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; MALE; METABOLISM; METASTASIS; MIDDLE AGED; PAIN;

ADULT; AGED; BONE NEOPLASMS; DIPHOSPHONATES; DRUG RESISTANCE; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; NARCOTICS; PAIN; PILOT PROJECTS; QUALITY OF LIFE;

EID: 4444327076     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.07.054     Document Type: Article

References (31)

1. Coleman RE, Rubens RD: The clinical course of bone metastases from breast cancer. Br J Cancer 55:61-66, 1987
2. Body JJ, Mancini I: Bisphosphonates for cancer patients: Why, how and when? Support Care Cancer 10:399-407, 2002
3. Janjan N: Bone metastases: Approaches to management. Semin Oncol 28:28-34, 2001 (suppl 11)
4. Fulfaro F, Casuccio A, Ticozzi C, et al: The role of bisphosphonates in the treatment of painful metastatic bone disease: A review of phase III trials. Pain 78:157-169, 1998
5. Body JJ: Bisphosphonates for metastatic bone pain. Support Care Cancer 7:1-3, 1999
6. Lucas LK, Lipman AG: Recent advances in pharmacotherapy for cancer pain management. Cancer Practice 10:14S-20S, 2002 (suppl 1)
7. Body JJ: Bisphosphonates in the treatment of metastatic breast cancer. J Mammary Gland Biol Neoplasia 6:477-485, 2001
8. Body JJ, Bartl R, Burckhardt P, et al: Current use of bisphosphonates in oncology. J Clin Oncol 16:3890-3899, 1998
9. Pavlakis N, Stockler M: Bisphosphonates for breast cancer (Cochrane Review). Oxford, United Kingdom, The Cochrane Library, Issue 2, 2002 (update software)
10. Tubiana-Hulin M, Beuzeboc P, Mauriac L, et al: Double-blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases. Bull Cancer 88:701-707, 2001
11. Ernst DS, MacDonald RN, Paterson AHG, et al: A double-blind, crossover trial of intravenous clodronate in metastatic bone pain. J Pain Symptom Manage 7:4-11, 1992
12. Ernst DS, Brasher P, Hagen N, et al: A randomized, controlled trial of intravenous clodronate in patients with metastatic bone disease and pain. J Pain Symptom Manage 13:319-326, 1997
13. Robertson AG, Reed NS, Ralston SH: Effect of oral clodronate on metastatic bone pain: A double-blind, placebo-controlled study. J Clin Oncol 13:2427-2430, 1995
14. Cascinu S, Graziano F, Alessandroni P, et al: Different doses of pamidronate in patients with painful osteolytic bone metastases. Support Care Cancer 6:139-143, 1998
15. Koerberle D, Bacchus L, Thuerlimann B, et al: Pamidronate treatment in patients with malignant osteolytic bone disease and pain: A prospective randomized double-blind trial. Support Care Cancer 7:21-27, 1999
16. McCloskey EV, MacLennan IC, Drayson MT, et al: Randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma: MRC Working Party on Leukaemia in Adults. Br J Haematol 100:317-325, 1998
17. Hortobagyi GN, Theriault RL, Lipton A, et al: Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate: Protocol 19 Aredia Breast Cancer Study Group. J Clin Oncol 16:2038-2044, 1998
18. Rosen LS, Gordon D, Kaminski M, et al: Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: A phase III, double-blind, comparative trial. Cancer J 7:377-387, 2001
19. Body JJ, Diel IJ, Lichinitser MR, et al: Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol 14:1399-1405, 2003
20. Bruera E, Michaud M, Vigano A, et al: Multidisciplinary symptom control clinic in a cancer center: A retrospective study. Support Care Cancer 9:162-168, 2001
21. Jacox A, Carr DB, Payne R, et al: Management of Cancer Pain: Quick Reference Guide for Clinicians (Clinical Practice Guideline No. 9, AHCPR Publication No. 94-0592). Rockville, MD. Agency for Health Care Policy and Research. United States Department of Health and Human Services, Public Health Service, March 1994
22. Kaasa T, Loomis J, Gillis K, Bruera E: The Edmonton Functional Assessment Tool: Preliminary development and evaluation for use in palliative care. J Pain Symptom Manage 13:10-19, 1997
23. Oken MM, Creech RH, Tormey DC, et al: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649-655, 1982
24. Bruera E, Kuehn N, Miller MJ, et al: The Edmonton symptom assessment system (ESAS): A simple method for the assessment of palliative care patients. J Palliat Care 7:6-9, 1991
25. Dumon JC, Wantier H, Mathieu F, et al: Technical and clinical validation of a new immunoradiometric assay for human osteocalcin. Eur J Endocrinol 135:231-237, 1996
26. Vinholes JJF, Purohit OP, Abbey ME, et al: Relationships between biochemical and symptomatic response in a double-blind randomised trial of pamidronate for metastatic bone disease. Ann Oncol 8:1243-1250, 1997
27. Adami S, Zamberlan N: Adverse effects of bisphosphonates: A comparative review. Drug Saf 14:158-170, 1996
28. Bounameaux HM, Schifferli J, Montani JP, et al: Renal failure associated with intravenous bisphosphonates. Lancet 1:471, 1983
29. Body JJ: Dosing regimens and main adverse events of bisphosphonates. Semin Oncol 28:49-53, 2001 (suppl 11)
30. Heidenreich A, Ohlmann C, Olbert P, et al: High-dose ibandronate is effective and well tolerated in the treatment of pain and hypercalcaemia due to metastatic urologic cancer. Eur J Cancer 1:S270, 2003 (suppl 5)
31. Saad F, Gleason DM, Murray R, et al: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94:1458-1468, 2002